The FDA has issued an approvable letter which is the last step before final approval in the United States. Primary Biliary Cirrhosis PBC is a chronic, progressive cholestatic liver disease of unknown origin. Some 50,000 people in the United States have the disease. After diagnosis, patients currently survive an average of 10 years.
Liver transplant is the only alternative treatment for end-stage patients.
It improves the survival rate of patients and delays liver transplantation. Axcan and Schwarz each have a 50 percent ownership interest in Axcan Schwarz. Use of this site signifies your agreement to the terms of use.